Ruol A, Stephens J K, Michelassi F, Segalin A, Chiarelli S, Peracchia A, Skinner D B, Little A G
First Department of Surgery, University of Padova, Italy.
J Surg Oncol. 1990 Jul;44(3):142-5. doi: 10.1002/jso.2930440304.
In order to investigate the value of ras oncogene expression as a prognostic indicator in esophageal squamous cell carcinoma, we evaluated the level of ras oncogene protein product (p21) in 52 specimens resected between 1977 and 1986. All patients were followed until death or for at least 2 years. Pathology slides and archival paraffin blocks were retrieved for confirmation of the original diagnosis, study of histopathologic features, and measurement of p21 content. P21 titers were obtained using the RAP-5 monoclonal antibody in a semiquantitative immunohistochemical assay. Titer was expressed as the highest dilution of antibody giving definitive staining using the avidin-biotin peroxidase method. Ras oncogene was expressed in 88.5% of the specimens. We did not find a significant correlation between ras expression and any of a variety of clinical and histopathologic prognostic parameters. Although patients' median survival after resection of specimens with ras oncogene expression was less than half the median survival after removal of tumors without such expression, this difference was not statistically significant. Further prospective investigations are needed to assess the role of ras oncogene evaluation in clinical practice.
为了研究ras癌基因表达作为食管鳞状细胞癌预后指标的价值,我们评估了1977年至1986年间切除的52个标本中ras癌基因蛋白产物(p21)的水平。所有患者均随访至死亡或至少2年。检索病理切片和存档石蜡块以确认原诊断、研究组织病理学特征并测量p21含量。使用RAP-5单克隆抗体通过半定量免疫组织化学分析获得p21滴度。滴度表示为使用抗生物素蛋白-生物素过氧化物酶法给出明确染色的抗体最高稀释度。88.5%的标本中表达了ras癌基因。我们未发现ras表达与各种临床和组织病理学预后参数之间存在显著相关性。尽管切除有ras癌基因表达标本后的患者中位生存期不到切除无此类表达肿瘤后中位生存期的一半,但这种差异无统计学意义。需要进一步的前瞻性研究来评估ras癌基因评估在临床实践中的作用。